Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers

Xenobiotica

Volumn 40, Issue 4, 2010, Pages 275-281

  Lei, H P ^a   Yu, X Y ^a   Xie, H T ^b,c   Li, H H ^b   Fan, L ^b   Dai, L L ^b   Chen, Y ^b   Zhou, H H ^b  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Anhui Provincial Center for Drug Clinical Evaluation   (China)

Author keywords

Bupropion; Interaction; Pharmacokinetics; St. Johns wort

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2B6; HYPERICUM PERFORATUM EXTRACT; RADAFAXINE; SOLARAY; UNCLASSIFIED DRUG; ZYBAN SR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TRANSFORMATION; HUMAN; MALE; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; SINGLE DRUG DOSE; SUSTAINED RELEASE FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HALF-LIFE; HUMANS; HYPERICUM; MALE; PLANT PREPARATIONS; TANDEM MASS SPECTROMETRY;

EID: 77949471545     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498250903509383     Document Type: Article

References (36)

1. Bauer S, Stormer E, Johne A, Kruger H, Budde K, Neumayer HH, Roots I, Mai I. (2003). Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St. John's wort in renal transplant patients. Br J Clin Pharmacol 55:203-211
2. Breidenbach T, Hoffmann MW, Becker T, Schlitt H, Klempnauer J. (2000a). Drug interaction of St. John's wort with cyclosporin. Lancet 355:1912.
3. Breidenbach T, Kliem V, Burg M, Radermacher J, Hoffmann MW, Klempnauer J. (2000b). Profound drop of cyclosporin A whole blood trough levels caused by St. John's wort (Hypericum perforatum).Transplantation 69:2229-2230
4. Butterweck V, Schmidt M. (2007). St. John's wort: role of active compounds for its mechanism of action and efficacy. Wien Med Wochenschr 157:356-361
5. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM. (2000). Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230
6. Faucette SR, Hawke RL, Shord SS, Lecluyse EL, Lindley CM. (2001). Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab Dispos 29:1123-1129
7. Foley KF, DeSanty KP, Kast RE. (2006). Bupropion: pharmacology and therapeutic applications. Exp Rev Neurotherapeut 6:1249-1265
8. Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. (2004). Effect of St. John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 76:323-329
9. Fugh-Berman A, Ernst E. (2001). Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 52:587-595
10. Goodwin B, Moore LB, Stoltz CM, McKee DD, Kliewer SA. (2001). Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 60:427-431
11. Greeson JM, Sanford B, Monti DA. (2001). St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology(Berl) 153:402-414
12. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC. (2003). The interaction between St. John's wort and an oral contraceptive. Clin Pharmacol Ther 74:525-535
13. Haynes KFS, Lindley C, LeCluyse E, Shord S, Hawke R. (2002). Evaluation of buproprion hydroxylation as a probe for cytochrome P450 2B6 activity in cultured human hepatocytes. Poster presented at the American College of Clinical Pharmacy Savannah, GA, USA, 10 April 2002.
14. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. (2002). St. John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 54:349-356
15. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ. (2000). CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176-1183
16. Hogeland GW, Swindells S, McNabb JC, Kashuba AD, Yee GC, Lindley CM. (2007) Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther 81:69-75.
17. Holm KJ, Spencer CM. (2000). Bupropion: a review of its use in the management of smoking cessation. Drugs 59:1007-1024
18. Ioannides C. (2002). Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 32:451-478
19. Izzo AA, Ernst E. (2001). Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 61:2163-2175
20. Jefferson JW, Pradko JF, Muir KT. (2005). Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther 27:1685-1695
21. Johne A, Schmider J, Brockmoller J, Stadelmann AM, Stormer E, Bauer S, Scholler G., Langheinrich M, Roots I. (2002). Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol 22:46-54.
22. Loboz KK, Gross AS, Williams KM, Liauw WS, Day RO, Blievernicht JK, Zanger UM, McLachlan AJ. (2006). Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther 80:75-84.
23. Mai I, Stormer E, Bauer S, Kruger H, Budde K, Roots I. (2003). Impact of St. John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 18:819-822
24. Mueller SC, Majcher-Peszynska J, Mundkowski RG. (2009). No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers. Eur J Clin Pharmacol 65:81-87
25. Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W, Sievers H, Bauer S, Frank B, Kundt G, Drewelow B. (2006). The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 62:29-36.
26. Murphy PA. (2002). St. John's wort and oral contraceptives: reasons for concern? J Midwife Women Hlth 47:447-450
27. Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K. (2003). Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther 74:326-333
28. Rengelshausen J, Banfield M, Riedel KD, Burhenne J, Weiss J, Thomsen T, Walter-Sack I, Haefeli WE, Mikus G. (2005). Opposite effects of short-term and long-term St. John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 78:25-33.
29. Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, Kirch W. (2007). Induction of intestinal P-glycoprotein by St. John's wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther 81:669-678
30. Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernas H. (2004). St. John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther 75:298-309.
31. Timbo BB, Ross MP, McCarthy PV, Lin CT. (2006). Dietary supplements in a national survey: prevalence of use and reports of adverse events. J Am Diet Assoc 106:1966-1974
32. Ute Godtel-Armbrust U, Metzger A, Kroll U, Kelber O, Wojnowski L. (2007). Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort. Naunyn-Schmiedeberg's Arch Pharmacol 375:377-382
33. Williams JW Jr, Holsinger T. (2005). St. John's for depression, worts and all. Br Med J 330:E350-1.
34. Wurglics M, Westerhoff K, Holoubek G, Schubert-Zsilavecz M, Mueller W. (2002). Aktuelle Johanniskrautforschung. Deutsche Apothekerzeitung 142:1153-1175
35. Xie HG, Kim RB. (2005). St. John's wort-associated drug interactions: short-term inhibition and long-term induction? Clin Pharmacol Ther 78:19-24.
36. Zanoli P. (2004). Role of hyperforin in the pharmacological activities of St. John's wort. CNS Drug Rev 10:203-218